Chikungunya disease and chloroquine treatment

Delogu, Ilenia; Lamballerie, Xavier de

doi:10.1002/jmv.22019

Cited by 56 publications

(42 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The use of aspirin must be avoided due to the risk of Reye syndrome. It has been suggested that chloroquine, being capable of reducing viral replication, could be effective in the prophylaxis and treatment of early-stage disease, although no efficacy has been demonstrated in the chronic phase [14][15][16]. Moreover, methotrexate has been used successfully in a group of patients with chronic destructive polyarthritis (ACPA+) after CHIK infection [14,17,18].…”

Section: Discussionmentioning

confidence: 99%

How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

et al. 2015

View full text Add to dashboard Cite

Post-chikungunya chronic inflammatory rheumatism (pCHIK-CIR) is one of the consequences that are impacting new endemic countries, such as those in the Americas. The relative frequency of pCHIK-CIR is highly variable, ranging from 14.4 % to 87.2 % (including variable number of patients and follow-up times). Based on those non-weighted values, it is difficult to estimate which would be the expected number of patients with CHIK who will develop CIR. For these reasons, we modeled weighted estimations based on pooled data extracted from those eight representative studies in order to provide cumulative proportion of pCHIK-CIR over time and median time of it, but also estimations of the number of patients with CHIK reported in Latin American countries (within a 95 % CI). This model estimated a prevalence of 47.57 % for pCHIK-CIR (95 % CI 45.08-50.13), with a median time to 50 % of pCHIK-CIR in 20.12 months. Given the reported number of patients with acute CHIK during 2014 in the Americas, our estimates suggest that from those patients, 385,835-429,058 patients will develop pCHIK-CIR. Despite the limitations of these estimates, the provided figures of pCHIK-CIR presented here are preliminary approximations of what the future burden of related rheumatic disease in the region as a consequence of CHIK infection for 2015-2016 could be, given the timeframe of median time of occurrence.

show abstract

Section: Discussionmentioning

confidence: 99%

How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Se ha sugerido que la cloroquina, siendo capaz de reducir la replicación viral, podría ser eficaz en la profilaxis y el tratamiento de la etapa temprana de la enfermedad, no habiéndose demostrado su eficacia en la fase crónica 33,34 . Por otra parte, el metotrexato ha sido utilizado con éxito en un grupo de pacientes con poliartritis crónica destructiva (CPP+) tras la infección por CHIKV 35,36 .…”

Section: Tratamientounclassified

Fiebre chikungunya. Manifestaciones reumáticas de una infección emergente en Europa

Horcada

Díaz-Calderón

Garrido

2015

Reumatología Clínica

View full text Add to dashboard Cite

“…Currently, there is no vaccine for the prevention of CHIKV infection, or a specific treatment for CHIKV infection and its potential sequelae. Non‐steroidal anti‐inflammatory drugs, steroids, and opioids are used to control some of the symptoms of chronic inflammatory arthritis …”

Section: Introductionmentioning

confidence: 99%

Chikungunya in solid organ transplant recipients, a case series and literature review

Rosso

Rodríguez

Cedano

et al. 2018

Transplant Infectious Dis

View full text Add to dashboard Cite

Chikungunya virus is a recent emerging arbovirus in Latin America, and the clinical manifestations can vary from fever and rash to severe chronic inflammatory arthritis. Few reports have been published regarding this infection in immunocompromised patients, including solid organ transplant recipients. We report a case series of solid organ transplant recipients with confirmed Chikungunya infection by positive reverse transcription polymerase chain reaction (RT-PCR), identified between January 2014 and December 2016. In addition, we conducted a literature review searching PubMed, EMBASE, and LILACS databases on Chikungunya infection in solid organ transplant recipients. Ten solid organ transplant recipients were included, consisting of 5 kidney, 4 liver, and 1 liver/kidney transplant recipient. Mean age of the transplant recipients was 47 years, and the most frequent symptoms of Chikungunya infection were arthralgia and fever. None of the patients required treatment in the intensive care unit, no deaths or graft rejection occurred. None of our patients had recurrent arthritis during 3-month follow-up period after the infection. Twenty-one cases of Chikungunya virus were identified in the literature review. Most cases had a benign clinical course with no severe complications, death, or chronic inflammatory arthritis. In conclusion, Chikungunya infection in solid organ transplant recipients has a benign course and has no chronic recurrent arthritis. It is possible that the immunosuppression regimen could decrease the risk of severe or chronic inflammatory manifestations in solid organ transplant recipients infected with Chikungunya.

show abstract

Chikungunya disease and chloroquine treatment

Cited by 56 publications

References 16 publications

How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

How many patients with post-chikungunya chronic inflammatory rheumatism can we expect in the new endemic areas of Latin America?

Fiebre chikungunya. Manifestaciones reumáticas de una infección emergente en Europa

Chikungunya in solid organ transplant recipients, a case series and literature review

Contact Info

Product

Resources

About